An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer

Abstract Background Immuno-radiotherapy may improve outcomes for patients with advanced solid tumors, although optimized combination modalities remain unclear. Here, we report the colorectal (CRC) cohort analysis from the SABR-PDL1 trial that evaluated the PD-L1 inhibitor atezolizumab in combination...

Olles dieđut

Bibliográfalaš dieđut

Váldodahkkit:	Antonin Levy, Daphné Morel, Matthieu Texier, Roger Sun, Jerome Durand-Labrunie, Maria E Rodriguez-Ruiz, Severine Racadot, Stéphane Supiot, Nicolas Magné, Stacy Cyrille, Guillaume Louvel, Christophe Massard, Loic Verlingue, Fanny Bouquet, Alberto Bustillos, Lisa Bouarroudj, Clément Quevrin, Céline Clémenson, Michele Mondini, Lydia Meziani, Lambros Tselikas, Rastilav Bahleda, Antoine Hollebecque, Eric Deutsch
Materiálatiipa:	Artigo
Giella:	Inglês
Almmustuhtton:	BMC 2024-03-01
Ráidu:	Molecular Cancer
Liŋkkat:	https://doi.org/10.1186/s12943-024-01970-8
Fáddágilkorat:	Lasit fáddágilkoriid Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!